( OTC-BB:TELK, OTC-QB:TELK )

News from MabVax Therapeutics Holdings, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 16, 2017, 07:05 ET MabVax Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company focused on the development of antibody-based...


Nov 13, 2017, 07:30 ET MabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...


Oct 31, 2017, 07:35 ET MabVax Therapeutics Provides Update on the MVT-5873 Phase 1 Clinical Program and Expansion of Preclinical Development Pipeline at the AACR-NCI-EORTC International Conference

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company focused on the development of antibody-based...


Oct 26, 2017, 07:30 ET MabVax Therapeutics to Present Three Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company focused on the development of antibody-based...


Oct 24, 2017, 07:30 ET MabVax Therapeutics Expands Intellectual Property Estate by Filing a New Patent Application on its Fully-Human Antibody Discoveries

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...


Oct 17, 2017, 07:00 ET MabVax Therapeutics Holdings, Inc. Provides Corporate Overview and Business Outlook

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...


Oct 11, 2017, 08:00 ET MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...


Oct 11, 2017, 07:59 ET MabVax Therapeutics Holdings, Inc. Announces $500,000 Registered Direct Offering

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...


Oct 06, 2017, 14:00 ET MabVax Stockholders Approve Remaining Proposal at Special Meeting of Stockholders

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to...


Oct 03, 2017, 18:35 ET MabVax Stockholders Approve Proposals at Special Meeting of Stockholders

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to...


Oct 03, 2017, 08:00 ET Novel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging Congress

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...


Sep 28, 2017, 17:30 ET MabVax Announces Adjournment of Special Meeting of Stockholders

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) a clinical-stage biotechnology company focused on the development of antibody-based products to...


Sep 22, 2017, 15:30 ET MabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct Offering

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...


Sep 13, 2017, 08:05 ET MabVax Therapeutics' HuMab-5B1 Antibody to be Featured in Presentations at the 2017 World Molecular Imaging Congress

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform...


Sep 12, 2017, 08:05 ET MabVax Therapeutics Holdings, Inc. Announces $2.0 Million Registered Direct Offering

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...


Sep 06, 2017, 08:05 ET MabVax Therapeutics Engages Greenhill & Co. as Advisor for Exploring Strategic Alternatives

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery...


Aug 22, 2017, 16:05 ET MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 Million Registered Direct Offering and is Engaging an Advisory Bank to Explore Strategic Alternatives

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...


Aug 14, 2017, 08:10 ET MabVax Therapeutics Holdings, Inc. Announces Pricing of Registered Direct Offering

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...


Jul 24, 2017, 08:00 ET MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody...


Jun 27, 2017, 08:05 ET MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company with a fully human antibody discovery...


Jun 14, 2017, 07:05 ET MabVax Therapeutics Reports Positive Phase 1 Results for MVT-2163 ImmunoPET Imaging Agent

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery...


Jun 07, 2017, 07:05 ET MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...


Jun 05, 2017, 07:00 ET MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting

SAN DIEGO, June 5, 2017 /PRNewswire/-- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), is a clinical-stage biotechnology company with a fully...


May 31, 2017, 07:05 ET MabVax Therapeutics Signs Research Agreement with Memorial Sloan Kettering Cancer Center to Develop Novel CAR T-Cell Based Anti-Cancer Immunotherapies for Treatment of Pancreatic and Small Cell Lung Cancers

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical stage oncology drug development company, announced today it entered into a sponsored...


May 25, 2017, 07:05 ET MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...